Dyslipidaemias articles from across Nature Portfolio

Using two complementary approaches to induce hypercholesterolemia in mice, Di Nunzio, Hellberg, Zhang, Ahmed et al. identified liver macrophages as key cells that organize the systemic responses to lipoproteins during the initial phases of atherosclerosis pathogenesis.

Three randomized clinical trials presented at ACC.24 demonstrate that olezarsen and plozasiran, RNA-based therapies that target APOC3, can robustly reduce plasma triglyceride levels in patients with moderate to severe hypertriglyceridaemia.

A new study identifies a group of gut bacteria that can metabolize cholesterol and are associated with lower plasma cholesterol levels.

A new study identifies a hormone that is secreted by the gut in response to cholesterol absorption and can inhibit cholesterol synthesis in the liver, which prevents an increase in circulating cholesterol levels.

A new approach to modify the epigenome can lead to durable silencing of Pcsk9 in mice, thereby reducing plasma LDL-cholesterol levels, according to a study published in Nature.

Aster proteins are involved in the non-vesicular transport of cholesterol derived from dietary lipids in the small intestine from the plasma membrane to the endoplasmic reticulum in enterocytes.

By regulating the condensation of the molecular transport machinery coat protein complex II (COPII), manganese ions contribute to the regulation of lipoprotein secretion and thereby the circulating lipid levels.